SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-20-046095
Filing Date
2020-08-11
Accepted
2020-08-11 16:03:56
Documents
2
Period of Report
2020-08-10

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3173
2 POA DOCUMENT poa.txt EX-24.4_932692 3626
  Complete submission text file 0001209191-20-046095.txt   8226
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

Mailing Address C/O ALIMERA SCIENCES, INC. 6120 WINDWARD PARKWAY, SUITE 290 ALPHARETTA GA 30005
Business Address
Snisarenko John (Reporting) CIK: 0001783264 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39112 | Film No.: 201092411